Keyphrases
Acute Lymphoblastic Leukemia
39%
Acute Myeloid Leukemia
36%
Adult Patients
8%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Allogeneic Transplantation
7%
B-cell Acute Lymphoblastic Leukemia (B-ALL)
9%
Busulfan
17%
CD19
7%
Chemotherapy
9%
Chimeric Antigen Receptor T Cells (CAR-T)
14%
Chimeric Antigen Receptor T-cell Therapy
15%
Complete Remission
17%
Complete Response
7%
Conditioning Regimen
9%
Confidence Interval
21%
First Complete Remission
10%
Fludarabine
18%
Gemtuzumab Ozogamicin
10%
Graft-versus-host Disease (GvHD)
24%
Haploidentical
7%
Hazard Ratio
19%
Hematopoietic Cell Transplantation
14%
Hematopoietic Stem Cell Transplantation
14%
High Risk
11%
Hyper-CVAD
6%
Large B-cell Lymphoma
6%
Leukemia Patients
9%
Melphalan
11%
Minimal Residual Disease
19%
Multiple Myeloma
18%
Multiple Myeloma Patients
8%
Multivariate Analysis
8%
Myeloablative
9%
Myelodysplastic Syndrome
14%
Non-relapse Mortality
19%
Older Adults
7%
Older Patients
7%
Overall Survival
33%
Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
14%
Post-transplantation Cyclophosphamide (PTCy)
11%
Pretransplant
11%
Progression-free Survival
16%
Reduced-intensity Conditioning
9%
Relapse Risk
6%
Relapsed or Refractory
12%
Stem Cell Transplantation
9%
Transplant Outcomes
11%
Transplantation
14%
Tyrosine Kinase Inhibitor
8%
Unrelated Donor
13%
Medicine and Dentistry
Acute B-Cell Lymphoblastic Leukemia
7%
Acute Graft Versus Host Disease
5%
Acute Lymphoblastic Leukemia
49%
Acute Lymphocytic Leukemia
6%
Acute Myeloid Leukemia
38%
Adolescence
6%
Allogeneic Hematopoietic Stem Cell Transplantation
17%
Allogeneic Stem Cell Transplantation
21%
Allograft
10%
Autologous Hematopoietic Stem Cell Transplantation
14%
Autologous Stem Cell Transplantation
12%
B Cell
6%
Busulfan
13%
Cell Therapy
8%
Cell Transplantation
36%
Chimeric Antigen Receptor
10%
Chimeric Antigen Receptor T-Cell
7%
Chimeric Antigen Receptor T-Cell Immunotherapy
15%
Chronic Myelogenous Leukemia
5%
Clinical Trial
7%
Comorbidity
6%
Conditioning
9%
Cumulative Incidence
6%
Cyclophosphamide
6%
Cytokine Release Syndrome
5%
Diseases
23%
Fludarabine
11%
Graft Versus Host Reaction
10%
Hazard Ratio
20%
Hematopoietic Cell
43%
Hematopoietic Stem Cell Transplantation
20%
Inotuzumab Ozogamicin
7%
Large-Cell Lymphoma
8%
Lenalidomide
6%
Leukemia
8%
Malignant Neoplasm
8%
Melphalan
9%
Minimal Residual Disease
21%
Multiple Myeloma
24%
Multivariate Analysis
8%
Myelodysplastic Syndrome
18%
Overall Survival
40%
Philadelphia 1 Chromosome
10%
Progression Free Survival
20%
Reduced Intensity Conditioning
7%
Stem Cell Therapy
8%
Stem Cell Transplant
15%
T Cell
13%
Transplantation
42%
Tyrosine-Kinase Inhibitor
10%
Immunology and Microbiology
Acute Graft Versus Host Disease
11%
Allogeneic Hematopoietic Stem Cell Transplantation
21%
Allogeneic Stem Cell Transplantation
17%
Allograft
11%
Autologous Hematopoietic Stem Cell Transplantation
10%
Autologous Stem Cell Transplantation
9%
B Cell
11%
CD19
8%
Cell Transplantation
38%
Chimeric Antigen Receptor
10%
Chimeric Antigen Receptor T-Cell Therapy
7%
Chronic Graft Versus Host Disease
5%
Conditioning
26%
Cord Blood Stem Cell Transplantation
5%
Cyclophosphamide
16%
Disease Free Survival
5%
Drug Megadose
8%
Engraftment
8%
Graft-Versus-Host Disease
17%
Hematopoietic Cell
42%
Hematopoietic Stem Cell Transplantation
19%
Inotuzumab Ozogamicin
5%
Lenalidomide
5%
Multiple Myeloma
23%
Myeloid
30%
Overall Survival
35%
Philadelphia 1 Chromosome
7%
Progression Free Survival
19%
Stem Cell
5%
Stem Cell Transplant
7%
T Cell
18%
Tyrosine
6%